Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acthar Gel in Membranous Lupus Nephritis
NCT01926054Phase 4Withdrawn
- Sponsor
- The Ohio State University
- Start
- Jul 2013
- Primary completion
- Feb 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of repository corticotropin injection in Membranous lupus nephritis, sponsored by The Ohio State University. Primary endpoint: Number of participants with adverse events at 12 months. Planned start Jul 2013; status: withdrawn.
02
Drugs
repository corticotropin injection
03
Conditions
Membranous lupus nephritis
Beyond the preview
Go deeper on NCT01926054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01926054.